DDInter381 DDInter1024
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Cinacalcet {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lapatinib
Cinacalcet {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Lapatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Fluoxetine
Fluoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Cinacalcet {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Lapatinib
Cinacalcet {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Cinacalcet {u} (Compound) causes {v} (Side Effect) Dyspnoea
Dyspnoea {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Cinacalcet {u} (Compound) causes {v} (Side Effect) Metastatic neoplasm
Metastatic neoplasm {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Propranolol
Propranolol {u} (Compound) resembles {v} (Compound) Atomoxetine
Atomoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Cinacalcet {u} (Compound) resembles {v} (Compound) Fluoxetine
Fluoxetine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lapatinib
Cinacalcet {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Cinacalcet (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Cinacalcet (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Lapatinib (Compound)
Cinacalcet (Compound) resembles Fluoxetine (Compound) and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Cinacalcet (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Cinacalcet (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Cinacalcet (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Cinacalcet (Compound) causes Metastatic neoplasm (Side Effect) and Metastatic neoplasm (Side Effect) is caused by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Cinacalcet (Compound) resembles Propranolol (Compound) and Propranolol (Compound) resembles Atomoxetine (Compound) and Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Cinacalcet (Compound) resembles Fluoxetine (Compound) and Fluoxetine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Cinacalcet (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lapatinib